Susquehanna International Group, LLP Geron Corp Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$4.17 - $4.99 $892,797 - $1.07 Million	-214,100 Reduced 39.31%	330,600 $1.5 Million
Q2 2024 Aug 15, 2024	SELL	$3.1 - $5.09 $988,280 - $1.62 Million	-318,800 Reduced 36.92%	544,700 $2.31 Million
Q1 2024 May 07, 2024	BUY	$1.75 - $3.44 $968,100 - $1.9 Million	553,200 Added 178.28%	863,500 $2.85 Million
Q4 2023 Feb 14, 2024	SELL	$1.74 - $2.31 $79,344 - $105,336	-45,600 Reduced 12.81%	310,300 $654,000
Q3 2023 Nov 14, 2023	SELL	$2.11 - $3.28 $321,986 - $500,527	-152,600 Reduced 30.01%	355,900 $754,000
Q2 2023 Aug 11, 2023	BUY	$1.97 - $3.69 $86,877 - $162,729	44,100 Added 9.5%	508,500 $1.63 Million
Q1 2023 May 16, 2023	BUY	$2.14 - $3.4 $324,852 - $516,120	151,800 Added 48.56%	464,400 $1.01 Million
Q4 2022 Feb 14, 2023	SELL	$2.03 - $2.42 $151,843 - $181,016	-74,800 Reduced 19.31%	312,600 $756,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $262,357 - $461,874	157,100 Added 68.22%	387,400 $907,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.53B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.